Burcon NutraScience GAAP EPS of C$0.62, revenue of C$1.04M

Burcon NutraScience reported Q2 GAAP EPS of C$0.62 and revenue of C$1.04M. The company's press release provided these financial updates. Investors may consider this data for trading decisions.

Original reporting
Published Nov 16, 2026, 9:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BRCNF
Neutral
medium confidence
Mentioned
$BRCNF
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$BRCNFNeutralMed
01

Why it matters

The disclosed GAAP EPS and revenue are the actionable inputs for an earnings reaction trade, but the excerpt lacks consensus comparison and forward guidance.

02

Market read

Traders can use the reported quarterly EPS and revenue to reassess near-term valuation and sentiment, though the excerpt lacks beat/miss context.

03

What to watch

For this issuer, investors typically focus on liquidity, R&D milestones, and forward outlook; none of that is included in the provided text.

Relevance 7/10Novelty 7/10Timing: after-hours earnings release (Nov 16, 2026, 4:29 PM ET)

Background

The article is a Seeking Alpha earnings news blurb referencing Burcon NutraScience’s press release for Q2 results.

Company-level read

Ticker impact

$BRCNFNeutralMedium confidence
Context

Burcon NutraScience reports Q2 GAAP EPS of C$0.62 and revenue of C$1.04M in its earnings release.

Expected impact

Likely modest volatility as traders compare the reported EPS and revenue to prevailing expectations and guidance context.

Evidence & confidence

The piece contains the company’s own quarterly results numbers, but provides no guidance, segment detail, or explicit beat/miss versus consensus in the text provided.

Market effects

Adds another data point for small-cap nutraceutical/biotech earnings momentum, but no sector-wide read-through is provided.

Limited, as the article is company-specific and does not cite broader regional macro or peer actions.

Low, no international regulatory or supply-chain developments are mentioned.

Counterpoint

Because the article provides only GAAP EPS and revenue, traders may discount the print if cash burn, pipeline progress, or forward guidance are the real drivers.

Key entities

  • Burcon NutraScience Corporation

    Reports Q2 GAAP EPS of C$0.62 and revenue of C$1.04M in its earnings release.

Related articles

MedAI 8/10

Burcon NutraScience Corporation: Burcon Reports Fiscal 2027 First Quarter Results, Advances Commercial Revenue Ramp

Burcon NutraScience (TSX: BU, OTCQB: BRCNF) reported fiscal 2027 Q1 results for the three months ended June 30, 2026. Revenue rose to C$1.3 million, up 54% sequentially and 273% year over year. Net loss was C$3.8 million (C$0.30/share). Cash was C$0.9 million with negative working capital. The company also announced a C$1.4 million related-party loan and a private placement of convertible debentures up to C$8.1 million.

$XPMed

XP Q3 Earnings Call Highlights

XP Inc. reported Q3 earnings, with SGA expenses rising 12% YoY to BRL 1.9B. The company announced a BRL 1.5B share buyback and BRL 1.3B in dividends. Client assets reached BRL 2.2T, up 15% YoY. XP expects 10% revenue growth in 2027, with slower expense growth. Credit and market risks were discussed, with mark-to-market losses totaling nearly BRL 400M in H1.

$LGOMed

Largo Inc.: Largo Reports Q3 2026 Financial Results Start to Reflect Diversification into Copper, Gold and Platinum Group Metals as By-Product of Its Core Vanadium Business and $3.5 Million in Operating Cash Flow

Largo Inc. (LGO) reported Q3 2026 results, with revenues up 5% to $34.9M, including $2.6M from new copper, gold, and PGM by-products. Vanadium production fell 20.6% due to a strategy shift, but sales remained stable. Operating cash flow was $3.5M, and the company aims to diversify revenue and improve margins. Net loss narrowed to $32M from $36.6M YoY. Largo is evaluating a Nasdaq listing transfer to meet compliance requirements.

$GPROMed

GoPro year-over-year Q3 revenue declines 41%

GoPro reported Q3 revenue of $96.2M, down 41% YoY, and a net loss of $48M. The company delayed its earnings report due to merger-related financial procedures. The merger with Starman Optical, announced in September, is still on track, with the closing deadline extended to March 2027. GoPro will not provide financial guidance due to the pending transaction.

$IQMedAI 9/10

Why iQIYI Stock Tanked Today

iQIYI (IQ) reported Q3 revenue of 6B yuan ($900M), down 10% YoY, missing estimates. Membership revenue fell 6%. GAAP net loss narrowed to 173M yuan ($26M) from 249M yuan ($37M) YoY, but still wider than expected. The company is shifting focus to long-form video and AI. Shares dropped 18% post-earnings.